Advertising - BiopharmaDirect

Advertising

Advertising

Convert Our Audience into Your Customers

The world's largest community of biopharmaceutical professionals is waiting for you.

● Website Banner Advertising
  • The most powerful platform in biopharmaceutical field, with direct reach to more than 100,000 engaged visitors every month
  • More than 1.5 million pageviews per year
  • High-viewability positions deliver maximum ROI
  • Standard ROS positions fully optimized to meet AdSense and IAB standards
  • Native Ads showcase your expert content alongside BiopharmaDirect editorial content for maximum impact
  • Topic Takeover establishes your dominance with ownership of all ad positions across a specific topic
  • Big Splash Roller commands attention above the fold
  • Targeted Offsite Display extends your campaign to known, registered BiopharmaDirect readers wherever they may be browsing on the web
Terms and Conditions
  • All banner and keyword positions are sold on a first come, first served basis.
  • ROS banner ads may be changed once per month at no charge. Additional changes will incur a 25% change fee.
  • Banner advertising materials are due five days prior to the campaign start date unless specified otherwise. If banner material is received after the scheduled campaign start date, every attempt will be made to achieve impression levels booked, but the advertiser is still responsible for payment of the full amount of impressions booked for that time frame.
  • If there is a discrepancy between the third party and BiopharmaDirect of 10% or less of the total amount of impressions at the end of the campaign, then BiopharmaDirect would bill in full. If the rate of the discrepancy is above 10%, BiopharmaDirect will bill based on the original contracted amount.
  • Cancellations 10 days or more from the campaign start date are subject to a cancellation fee equal to 50% of the total insertion order fee. Cancellations within 10 days of the campaign start date are subject to a cancellation fee equal to 100% of the total insertion order fee. Changing campaign start dates within 30 days of originally scheduled date is subject to a 25% change fee based on the original insertion order fee.

Join Our Newsletter for Free

Latest News

Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).

LEARN MORE

Pfizer Acquires Amplyx Pharmaceuticals

Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.

LEARN MORE

Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials

Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).

LEARN MORE